Linked Data API

Show Search Form

Search Results

1127289
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2019-05-16
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Drugs: Prices more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the affordability of medicines as a result of the redrafted WHO resolution entitled, Improving the transparency of markets for medicines, vaccines and other health-related technologies proposed by Italy on 29 April 2019. more like this
star this property tabling member constituency Liverpool, Walton more like this
star this property tabling member printed
Dan Carden more like this
star this property uin 255695 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-22more like thismore than 2019-05-22
star this property answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.</p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-22T14:32:11.803Zmore like thismore than 2019-05-22T14:32:11.803Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4651
unstar this property label Biography information for Dan Carden remove filter
1127173
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2019-05-16
star this property answering body
Department for International Development more like this
star this property answering dept id 20 more like this
star this property answering dept short name International Development more like this
star this property answering dept sort name International Development more like this
star this property hansard heading Developing Countries: Climate Change more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for International Development, pursuant to the Answer of 16 April 2019 to Question HL15044 on Developing Countries: Climate Change, how much of the £5.8 billion allocated to international climate finance between 2016-17 and 2020-21 will be spent on tackling loss and damage in climate-vulnerable countries. more like this
star this property tabling member constituency Liverpool, Walton more like this
star this property tabling member printed
Dan Carden more like this
star this property uin 255379 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-21more like thismore than 2019-05-21
star this property answer text <p>Action to avert, minimize and address loss and damage associated with climate change is intricately bound up with action on mitigation, adaptation, disaster risk reduction and disaster preparedness and response. We therefore do not see that attempting to define a separate category of finance for loss and damage as useful or practical. Of the £5.8bn on climate finance we have committed to spend from 2016-2021 the UK aims to spend 50% on adaptation and 50% on mitigation.</p> more like this
star this property answering member constituency Penrith and The Border more like this
star this property answering member printed Rory Stewart more like this
star this property question first answered
less than 2019-05-21T16:48:42.047Zmore like thismore than 2019-05-21T16:48:42.047Z
star this property answering member
4137
star this property label Biography information for Rory Stewart more like this
star this property tabling member
4651
unstar this property label Biography information for Dan Carden remove filter
1127214
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2019-05-16
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Drugs: Prices more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies, if the Government will withdraw its support for suggested amendments to remove every mention of high prices. more like this
star this property tabling member constituency Liverpool, Walton more like this
star this property tabling member printed
Dan Carden more like this
star this property uin 255380 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-21more like thismore than 2019-05-21
star this property answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.</p><p> </p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
255381 more like this
255382 more like this
star this property question first answered
less than 2019-05-21T16:12:54.06Zmore like thismore than 2019-05-21T16:12:54.06Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4651
unstar this property label Biography information for Dan Carden remove filter
1127215
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2019-05-16
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Drugs: Prices more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies, if the Government will take steps to help ensure that the recommendation to member states calls for mandatory rather than voluntary measures. more like this
star this property tabling member constituency Liverpool, Walton more like this
star this property tabling member printed
Dan Carden more like this
star this property uin 255381 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-21more like thismore than 2019-05-21
star this property answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.</p><p> </p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
255380 more like this
255382 more like this
star this property question first answered
less than 2019-05-21T16:12:54.12Zmore like thismore than 2019-05-21T16:12:54.12Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4651
unstar this property label Biography information for Dan Carden remove filter
1127216
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2019-05-16
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Drugs: Prices more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if the Government will support the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies. more like this
star this property tabling member constituency Liverpool, Walton more like this
star this property tabling member printed
Dan Carden more like this
star this property uin 255382 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-21more like thismore than 2019-05-21
star this property answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.</p><p> </p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
255380 more like this
255381 more like this
star this property question first answered
less than 2019-05-21T16:12:54.153Zmore like thismore than 2019-05-21T16:12:54.153Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4651
unstar this property label Biography information for Dan Carden remove filter